Trevena Reports Preliminary TRV045 Data From Two Proof-of-Concept Studies Evaluating S1PR Mechanism Of Action And CNS Target Engagement
Portfolio Pulse from Benzinga Newsdesk
Trevena has reported preliminary data from two proof-of-concept studies evaluating the S1PR mechanism of action and CNS target engagement of TRV045. The drug demonstrated a statistically significant analgesic effect in a capsaicin-induced model of neuropathic pain in a target engagement POC study.
September 06, 2023 | 11:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Trevena's TRV045 has shown promising preliminary results in POC studies, which could potentially boost the company's stock.
Positive preliminary results from proof-of-concept studies are generally seen as a positive signal by investors, as they indicate that a drug has potential for further development and eventual commercialization. This could lead to increased investor confidence in Trevena, potentially driving up the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100